The Prevalence of PD-L1 Expression in Lung Cancer

Yu-Chen Chang, Ping-Chih Hsu, Shih-Hung Li, Shih-Hua Weng, Chih-Hsi Kuo, Tai-Yun Yang and Chien-Ying Liu

Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan
Department of Medicine, Chang Gung University, Taoyuan, Taiwan
Department of Thoracic Medicine, Division of Pulmonary Oncology, Chang Gung Memorial Hospital, Taiwan

^*Correspondance to: Chien-Ying Liu 

 PDF  Full Text Research Article | Open Access

Abstract:

Background: To find out the factors which influence the expression rate of PD-L1 by routine clinical parameters and simplified the therapeutic strategies for immune checkpoint inhibitor treatment, we profiled the relationships between of PD-L1 expression rate with clinical parameters (gender, smoking status, body weight, clinical) and some biomarkers for targeted therapy (EGFR, ALK).Methods: We enrolled in 500 patients with lung cancer diagnosis and further biopsy specimens, including 371 Adenocarcinoma (AD), 57 Squamous Cell Carcinoma (SCC), 9 small cell carcinoma, and 63 other Non-Small Cell Lung Cancer (NSCLC), and analyzed by using immuno histochemistry and cancer molecular study.Result: We found that 21.0% of total specimens (105 cases) showed strong positive PD-L1 expression on Tumor Cells (TC), and 45.8% (229 cases) for weak positive expression rate. We also found that there’s no significance difference in most parameters or biomarkers except clinical stage in adenocarcinoma, which showed apparent lower expression rate than higher infiltration stages.Conclusion: We concluded that our trial can provide some evidences which shows different PD-L1 expression situation in different stages, especially in the subtype of AD and SCC, which may become a good reference for physicians to make strategies to treat lung cancer.

Keywords:

Cite the Article:

Chang Y-C, Hsu P-C, Li S-H, Weng S-H, Kuo C-H, Yang T-Y, et al. The Prevalence of PD-L1 Expression in Lung Cancer. Clin Oncol. 2019; 4: 1591.